Giblin 2011.

Methods	Single‐center, randomized, double‐blind, placebo‐controlled, parallel‐group trial Country: United States Number of study sites: 1 Statistical methods: modified ITT (all randomized children/adolescents who had both a baseline and a post‐randomization primary outcome assessment)
Participants	Sample size: 24 children/adolescents with an ADHD diagnosis according to DSM‐IV‐TR criteria Dropouts: 0 Psychiatric comorbid conditions: NR Age range: 6 years to 12 years Mean age (SD): 9.65 (2.2) years Sex: 10 (42%) males ADHD subtype: NR
Interventions	Four interventions (24 children/adolescents participated in one of four interventions): Lisdexamphetamine (long acting), 30 mg/day, (n = 3) Lisdexamphetamine, (long acting), 50 mg/day, (n = 11) Lisdexamphetamine, (long acting), 70 mg/day, (n = 2) Placebo (n = 8) Duration: 28 days
Outcomes	Relevant outcomes: ADHD core symptom severity, assessed with ADHD Rating Scale, Fourth Version (investigator) and Conners' Parent Rating Scale ‐ Revised: Short Form* Clinical impression, assessed with Clinical Global Impression ‐ Severity scale Adverse events Other outcomes: Sleep onset latency, assessed with polysomnography Wake time after sleep onset, assessed with polysomnography and actigraphy Number awakenings after sleep onset, assessed with polysomnography Total sleep time, assessed with polysomnography and actigraphy Sleep efficiency, assessed with actigraphy
Notes	ClinicalTrials.gov identifier: not available Authors' affiliation: private organization and pharmaceutical industry Study funding: pharmaceutical industry *Unpublished data sought on both outcome measures on three separate occasions but not obtained
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Method of random sequence generation not described
Allocation concealment (selection bias)	Unclear risk	Method of allocation concealment not described
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Incomplete outcome data not addressed; number of completers not reported
Selective reporting (reporting bias)	Unclear risk	Study protocol not available and the possibility of reporting bias could not be assessed
Other bias	Low risk	Study appears to be free of other biases
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Blinding of participants and personnel not described
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Blinding of outcome assessment not described